Exploring the role of ADAMTSL2 across multiple cancer types: A pan-cancer analysis and validated in colorectal cancer
In summary, we conducted a comprehensive pan-cancer analysis of ADAMTSL2 and we demonstrated that ADAMTSL2 may serve as a novel prognostic biomarker and immunotherapy target in COADREAD.
Authors
- Qing-xin Yu
- Dengxiong Li (ORCID: https://orcid.org/0000-0002-1943-6758)
- Jun J. Yang (ORCID: https://orcid.org/0000-0002-0770-9659)
- Ruicheng Wu (ORCID: https://orcid.org/0009-0007-2403-1302)
- Dechao Feng (ORCID: https://orcid.org/0000-0002-8267-9920)
- Quan Yuan (ORCID: https://orcid.org/0000-0002-9202-6878)
- Chun-nian Wang
- Jie Wang (ORCID: https://orcid.org/0000-0002-5852-9754)
- Jing Jin (ORCID: https://orcid.org/0009-0002-3774-6546)
- Yongping Zhang (ORCID: https://orcid.org/0000-0003-1920-5885)
- Zhouting Tuo (ORCID: https://orcid.org/0000-0002-9806-2562)
Institutions
- Army Medical University (CN)
- Sichuan University (CN)
- Daping Hospital (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1007/s12672-024-01401-6
- Citations
- 4
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- China Scholarship Council